logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus | Conference Material / Slide Presentation | MSF Science Portal
Conference Material
|Slide Presentation

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N, Alvarez JL, Sitali N, Sinha A, Skrahina A
Download
Similar Content
Abstract
|Abstract
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Video
|Video
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Loading...
No abstract available

Countries

Belarus

Subject Area

antibiotic resistancetuberculosisantimicrobial resistance

Languages

English
DOI
10.57740/3sk2-bf43
Published Date
07 Jun 2023
Conference
MSF Scientific Day International 2023
Linked Content
Conference Material
|Abstract
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Conference Material
|Video
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023